Dengue is one of the most prevalent mosquito-borne viral disease in humans and is caused by four distinct serotypes (DENV 1–4). DENV are mainly transmitted by
Aedes mosquitoes and distributed in more than 100 countries in tropical and subtropical areas. More than 2.5 billion people are at risk of dengue infection in the world. The WHO estimates that more than 50 million dengue infections and 20,000 dengue-related deaths occur annually worldwide [
1]. Another study estimated that there were 390 million dengue infections including 96 million apparent dengue infections in 2010 [
2].
DENV cause a spectrum of diseases ranging from subclinical manifestations or a mild, self-limiting disease, dengue fever (DF), to a more severe disease, dengue hemorrhagic fever (DHF), which can progress to dengue shock syndrome (DSS) and death. Previous studies reported that cross-reacting antibodies enhanced dengue infection in humans and antibody dependent enhancement (ADE) had been proposed as the early mechanism underlying DHF/DSS [
3‐
7]. Moreover, recent studies have reported that human antibody responses after dengue virus infection were highly cross-reactive with Zika virus and was able to drive ADE of Zika infection [
8,
9]. Seroprevalence of dengue IgG antibodies was investigated in many countries where DENV are endemic. Jeewandara C et al. reported that 68.2% of individuals were seropositive for dengue in Sri Lanka and a significant rise in the age stratified seroprevalence rates was observed [
10]. Mazaba-Liwewe ML et al. reported the first seroprevalence of dengue specific IgG antibodies in Western and North-Western provinces of Zambia indicating that 4.1% of the participants tested positive for dengue IgG in these areas [
11]. Moreover, seroprevalence of dengue was also investigated in India, Thailand, Gabonese, Kenya, Saudi Arabia, Singapore, Tanzania, Sudan and factors associated with it were also explored [
12‐
19]. However, the duration of dengue IgG antibodies and factors associated with duration remain unclear in China. Here, we investigated seroprevalence of dengue IgG antibodies among symptomatic persons and asymptomatic individuals three years after infection and analyzed associated factors.